Barclays analyst Etzer Darout initiated coverage of Monopar Therapeutics (MNPR) with an Overweight rating and $125 price target The firm launched coverage of eight companies across inflammation and immunology, rare disease, and oncology. While small- and mid-cap biotechnology names have binary risk, investments supported by prior clinical data or de-risked mechanisms of actions represent risk/reward that is skewed to the upside, the analyst tells investors in a research note. Barclays believes the market is rewarding new mechanisms and modes of action that potentially improve dosing frequency and compliance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics Inc.: Promising Prospects with ALXN1840 Acquisition and Wilson’s Disease Market Potential
- Monopar Therapeutics price target raised to $142 from $80 at Raymond James
- Monopar Therapeutics price target raised to $115 from $77 at Oppenheimer
- Monopar Therapeutics price target raised to $105 from $70 at H.C. Wainwright
- Monopar Therapeutics price target raised to $85 from $60 at Chardan